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variances. RESULTS: Data were available for 1669 employees
with FD and a control group of (274,206) employees without
FD. The FD group’s costs (per employee/year) were twice as high
($3676) summed across all direct medical and work absence
measures (P < 0.0001). The individual differences (favoring FD)
in medical and pharmacy costs were $3420 and $365, respec-
tively (both P < 0.0001). Work absence costs had differences of
$103 (SL, P < 0.0001), $104 (STD, P = 0.0370), $7 (LTD, P =
0.6551). Measured units of productivity were 2 units less/hour
with the FD group (P = 0.055). CONCLUSION: This study con-
ﬁrms earlier work from Sweden, but shows that in the US, FD
can be costly to employers. Physicians and patients need more
education on the ROME II criteria and how to integrate this
information into improving medical and pharmaceutical costs.
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OBJECTIVES: The risk of gastrointestinal ulcers is enhanced by
non-steroidal anti-inﬂammatory drugs (NSAID). Proton pump
inhibitors (PPI) are used for gastroprotection, but their effec-
tiveness has been documented only in few studies (Hooper et al.
BMJ 2004; 329:948–57). We therefore investigated in the gas-
troprotective effects of PPI on diclofenac-induced ulcer risk.
METHODS: A nested case control study was performed based
on claims data from a large German sickness fund. A cohort was
constructed consisting of all beneﬁciaries enrolled in the health
plan continuously from 2000 until 2004. Cases had an inpatient
treatment due to peptic ulcer starting at or after January 1st 2003
with the case onset being the index date. All other beneﬁciaries
were randomly allocated to an index date, and ten controls per
case were drawn. For the 90 days before the index date it was
checked, if diclofenac and/or PPI were dispensed. The inﬂuence
of diclofenac alone as well as with concomitant PPI prescription
on ulcer risk was analysed using logistic regression models.
RESULTS: We identiﬁed 979 cases and 10,319 controls in the
cohort of 752,613 beneﬁciaries. The stratiﬁed analysis accord-
ing to the prescription of diclofenac alone or in combination with
PPI showed that diclofenac prescriptions within the 90 days
before the index day increased the risk for hospitalization due 
to peptic ulcer signiﬁcantly (odds ratio (OR) 3.21; 95%CI
2.59–3.96; p < 0.001). The risk was reduced (OR 1.26; 95%CI
0.68–2.30; p = 0.46), if PPI were prescribed concomitantly with
diclofenac. The signiﬁcance of the PPI effect was demonstrated
by inserting an interaction term in a regression model without
stratiﬁcation, where a risk reduction of 63% (OR 0.37; 95%CI
0.18–0.74; p = 0.005) was found. CONCLUSION: The con-
comitant prescription of PPI and diclofenac decreases the hospi-
talization risk due to peptic ulcer thus supporting the use of PPI
as gastroprotective agents.
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OBJECTIVES: To conduct an economic evaluation of terli-
pressin and octreotide used in the UK in the treatment of Bleed-
ing Oesophageal Varices (BOV). METHODS: Efﬁcacy results
from Cochrane meta-analyses were used. Baseline course of
disease and health-related utility (HRU) were retrieved from
published sources. Hospitalization related data were extracted
from HODaR, a large longitudinal database. Costs were
obtained from published sources, BNF and HODaR. A discrete
event simulation model was coded in VBA with the following
transition states: bleeding, no bleeding, no bleeding post-TIPS,
post-salvage surgery, and death. Weibull curves were ﬁtted to
estimate baseline survival, re-bleeding rates, and failure to
control bleeding. Simulations were run for up to ﬁve years since
initial bleeding. Prices were in UK£2005 and a discount rate of
3.5% was applied to costs and beneﬁts. Sensitivity analysis was
run with C++ dll engine. RESULTS: Terlipressin was found 
to be cost-effective with baseline values of ICER at 1 year
£5263/QALY (£3865/LYG) versus octreotide and £5618/QALY
(£4136/LYG) versus placebo. In baseline analysis octreotide was
not cost-effective against placebo. Based on deterministic and
probabilistic sensitivity analyses terlipressin remained cost-effec-
tive when compared to octreotide and placebo; it was cost-saving
for some of the varied input values. Distribution of ICER values
demonstrated cost-effectiveness of octreotide versus placebo, but
on CEAC curve, probability of cost-effectiveness of octreotide
and placebo were of the same magnitude: 24.0% and 23.4%,
respectively, at £20,000/QALY. The results were sensitive to
utility variables, but were generally robust and independent of
assumptions regarding baseline risk. Total Expected Value of
Perfect Information at 1 year varied from £928 to £220 per
patient depending on the range of variation of input variables.
CONCLUSIONS: Terlipressin is cost-effective when compared
to octreotide and placebo for the treatment of BOV in cirrhotic
patients. Further analysis is needed to establish cost-effectiveness
of octreotide versus placebo.
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ESOMEPRAZOLE AND RABEPRAZOLE FOR H. PYLORI
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OBJECTIVES: To assess the cost-effectiveness of two commonly
used triple therapies for H. pylori eradication in a public hospi-
tal in Hong Kong. METHODS: A prospective observational
design was adopted. Two cohorts of patients attending the GI
Specialty Clinic at the Prince of Wales Hospital with endoscop-
ically conﬁrmed non-ulcer dyspepsia and H. pylori positive con-
ﬁrmed by CLO Test were recruited. Informed consent from
patients and ethic approval from hospital were obtained. The
patients were consecutively recruited to receive esomeprazole +
amoxicillin + clarithromycin (EAC) or rabeprazole + amoxicillin
+ clarithromycin (RAC) therapies. One-week treatment was
given and urea breath test was performed after 4 weeks to
conﬁrm if eradication was successful. Initial treatment failures
were given quadruple rescue therapy (metronidazole + esomepra-
zole + danol + tetracycline). All health care resources including
clinic visits, laboratory procedures, medications, and profes-
sional services were recorded. RESULTS: One-hundred and three
and 96 patients were recruited to the EAC and RAC groups
respectively. The demographic characteristics were not signiﬁ-
cantly different except the RAC group had a lower rate of drink-
ing and smoking habits. The success rates for eradication for the
EAC and RAC groups were 88.5% and 85.4% respectively (p =
NS). The cost/successful eradication for EAC group and RAC
group was USD846 and USD843.7 respectively. The cost/suc-
cessful eradication after quadruple therapy was USD871 and
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USD868.3 for EAC and RAC groups respectively. The overall
cost/patient for H. pylori eradication was USD849 and USD
847.3 for EAC and RAC groups respectively. No signiﬁcant
adverse effects were experienced by patients in either group and
hence cost incurred in this area was minimal. CONCLUSION:
Esomeprazole and rabeprazole triple therapies appear to have
similar effectiveness in H. pylori eradication in patients with
non-ulcer dyspepsia. Rabeprazole triple therapy may have cost
savings when the whole population is considered.
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OBJECTIVE: Different treatments are available for Atopic Der-
matitis care. The preferences of patients should be taken into
consideration in the development of treatment strategies. The
aim of this study is to establish patients’ preferences and their
willingness-to-pay (WTP) on different AD treatment options.
METHODS: The CODA study was a naturalistic, multicentre,
longitudinal ambispective (retro-prospective), prevalence based
Cost-of-Illness study. Data on patients with moderate or severe
AD enrolled during ﬂare-up were collected. A discrete-choice-
experiment (DCE) was applied to enrolled patients. The follow-
ing attributes were considered to be important after interviewing
20 patients: pharmaceutical formulation (water-based cream vs
oil-based cream), the delay of The rapeutic response (4hours vs.
24hours vs. 48 hours), duration of therapeutic response (1 week
vs. 4 weeks vs. 8 weeks), long-term side effects and local side
effects (possible vs no). In order to estimate the WTP we added
the out-of-pocket cost of treatment (€0 vs. €50 vs. €100/month).
RESULTS: One-hundred-and-one of the 104 enrolled patients
(males 53.8%, mean age = 32.9 ± 11.8) ﬁlled in the DCE ques-
tionnaire. All attributes, excluding pharmaceutical formulation,
were relevant in patients’ choice (P < 0.001). Since the attribute
“cost” is determinant in the choice, a monetary value can be
assigned to each other relevant attribute. The conditional-probit-
model demonstrated that patients are willing-to-pay per month:
€104 for a “8 weeks therapeutic response” compared with 1
week; €47 for a treatment with “no local side effects”; €45 for
a treatment with “no long term side effects”; €21 for a “thera-
peutic response delay” of just one day. CONCLUSIONS: To our
knowledge, our study is the ﬁrst to elicit patients’ preferences
and their WTP for AD treatment. This information can guide
clinicians and decision makers to plan optimal health care.
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OBJECTIVES: To test whether the health of the mothers is
affected by the presence of a disabled or chronically-ill child.
METHODS: Using the National Longitudinal Survey of Chil-
dren and Youth (1994–2000), a nationally representative house-
hold survey in Canada, ordered Probit analysis was used to test
the effect of the presence of a disabled child on self-reported
health, controlling for other factors. Firstly, we modeled the
health effect of a disabled child in the house currently. Secondly,
utilizing the longitudinal aspect of the data, we modeled the
effect of the presence of a disabled child: a) currently only; 
b) previous years only; and c) both currently and previously.
Married and lone mothers are analyzed separately for children
aged 6–15 years of age in 2000 for a sample size of 5217 and
1177 for married and lone mothers, respectively. Bootstrap stan-
dard errors were calculated to account for multi-staged, non-
random survey design. To cope with causal inference issues we:
1) control for previous health status, and 2) test results using
propensity score matching (PSM). RESULTS: Evaluating at the
sample means, model 1 indicates a shift down in the health dis-
tribution for mothers with disabled children. There is a lower
probability of excellent health of 10[8.8–11.2] percentage points
for married mothers with a disabled child compared to house-
holds with no disabled children. Lone mothers show a difference
of 9[7–11] percentage points although health for lone mothers
is lower in general compared to married mothers. Model 2 shows
the strongest association for those households with a disabled
child both currently and in the past. PSM analysis conﬁrms our
results. CONCLUSIONS: The presence of a disabled or chroni-
cally-ill child has a statistically signiﬁcant effect on the health of
mothers. Consequences for maternal health are larger in the
long-run, if the child’s condition persists.
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OBJECTIVE: Validating a German child-friendly version of 
the EuroQol (EQ-5D) in different patient samples. METHODS:
After the translation from the original English version and
pretesting in cognitive interviews with native speakers of the
target language, the questionnaire was tested in two patient
groups (obesity and CF) and a sample of healthy children
between the ages of 8 and 16. For the validation three validated
instruments which measure hrQol in children and adolescents
were utilized (KINDL, KIDSCREEN and ChildDynHA). T-Tests
were conducted to audit potential differences in the EQ-5D
scores depending on age and sex of the children. Descriptive sta-
tistics were used to summarize EQ-5D scores as well as scores
of the additional instruments. RESULTS: The correlation
between the EQ-5D and the other instruments was quite high
(0.46–0.61). The highest correlation was found in the mobility
dimension. The CF groups shows the highest rates of reported
problems (42%), the rates of children who report no poblems
are quite similar for the obese and the healthy children (25 versus
27). CONLUSIONS: This pilot study of the questionaire showed
that the German child-friendly version of the EQ-5D is a valid
and feasible instrument to measure hrQol.
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In line with international trends, methylphenidate prescriptions
in Germany have been growing 20-fold over the last decade. This
has contributed to concern about potentially inappropriate and
excessive psychostimulant treatment for youths. OBJECTIVE:
To clarify methylphenidate prescriptions for children and ado-
